New research indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who halt conventional diet and exercise programs.
Research printed in a leading health publication shows that while overweight individuals frequently drop substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"People using such drugs need to be cognizant of the danger of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight in about a year and a half.
Comparing Therapies
The research, which examined dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
The team note that people who lose weight through dieting usually experience a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Quick Regain
Nutrition scientists believe the way of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in hunger is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, given the likelihood of weight regain, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the persistent nature of obesity," comparing it to managing conditions like hypertension.
User Testimonies
Users who have stopped the medication report a sudden resurgence of appetite.
"It was like a switch that goes on and I was suddenly starving," described a patient.
The struggle is worsened if individuals have not developed permanent lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while the jabs are potent agents for weight loss, they are not a magic cure and maintained weight loss hinges on ongoing lifestyle support.
